000280285 001__ 280285
000280285 005__ 20250831001839.0
000280285 0247_ $$2doi$$a10.1016/S0140-6736(25)01072-4
000280285 0247_ $$2pmid$$apmid:40783291
000280285 0247_ $$2ISSN$$a0140-6736
000280285 0247_ $$2ISSN$$a0023-7507
000280285 0247_ $$2ISSN$$a1474-547X
000280285 0247_ $$2altmetric$$aaltmetric:180127743
000280285 037__ $$aDZNE-2025-00940
000280285 041__ $$aEnglish
000280285 082__ $$a610
000280285 1001_ $$aRosenthal, Liana S$$b0
000280285 245__ $$aVesicular monoamine transport inhibitors: current uses and future directions.
000280285 260__ $$aLondon [u.a.]$$bElsevier$$c2025
000280285 3367_ $$2DRIVER$$aarticle
000280285 3367_ $$2DataCite$$aOutput Types/Journal article
000280285 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756384389_10794$$xReview Article
000280285 3367_ $$2BibTeX$$aARTICLE
000280285 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280285 3367_ $$00$$2EndNote$$aJournal Article
000280285 520__ $$aAdvancements over the past decade in understanding vesicular monoamine transporter 2 (VMAT2) inhibitors highlight their key role in the treatment of movement and neuropsychiatric disorders. VMAT2 is crucial for packaging neurotransmitters such as serotonin, dopamine, and norepinephrine into synaptic vesicles, facilitating their release and reuptake in synaptic transmission. VMAT2 inhibitors, such as tetrabenazine, deutetrabenazine, and valbenazine, show therapeutic efficacy in managing hyperkinetic movement disorders, including Huntington's disease, tardive dyskinesia, and Tourette's syndrome. These inhibitors modulate excessive synaptic activity by reducing neurotransmitter storage and release. Genetic variations, particularly in the cytochrome P450 enzyme family, influence VMAT2 inhibitor metabolism, necessitating personalised dosing to optimise efficacy and minimise adverse events. Recent studies have provided further structural insights into VMAT2 inhibition mechanisms, paving the way for the development of inhibitors with enhanced potency and selectivity. Leveraging pharmacogenetics for precision medicine and exploring VMAT2 inhibition in broader therapeutic contexts could revolutionise treatment frameworks for neurological and psychiatric conditions.
000280285 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x0
000280285 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280285 650_7 $$2NLM Chemicals$$aVesicular Monoamine Transport Proteins
000280285 650_7 $$0Z9O08YRN8O$$2NLM Chemicals$$aTetrabenazine
000280285 650_7 $$2NLM Chemicals$$aSLC18A2 protein, human
000280285 650_7 $$0P341G6W9NB$$2NLM Chemicals$$adeutetrabenazine
000280285 650_7 $$054K37P50KH$$2NLM Chemicals$$avalbenazine
000280285 650_7 $$0HG18B9YRS7$$2NLM Chemicals$$aValine
000280285 650_2 $$2MeSH$$aHumans
000280285 650_2 $$2MeSH$$aVesicular Monoamine Transport Proteins: antagonists & inhibitors
000280285 650_2 $$2MeSH$$aVesicular Monoamine Transport Proteins: metabolism
000280285 650_2 $$2MeSH$$aTetrabenazine: analogs & derivatives
000280285 650_2 $$2MeSH$$aTetrabenazine: therapeutic use
000280285 650_2 $$2MeSH$$aTetrabenazine: pharmacology
000280285 650_2 $$2MeSH$$aHuntington Disease: drug therapy
000280285 650_2 $$2MeSH$$aMovement Disorders: drug therapy
000280285 650_2 $$2MeSH$$aValine: analogs & derivatives
000280285 7001_ $$aFarag, Mena$$b1
000280285 7001_ $$0P:(DE-2719)2812578$$aAziz, N Ahmad$$b2$$udzne
000280285 7001_ $$aBang, Jee$$b3
000280285 773__ $$0PERI:(DE-600)1476593-7$$a10.1016/S0140-6736(25)01072-4$$gVol. 406, no. 10503, p. 650 - 664$$n10503$$p650 - 664$$tThe lancet$$v406$$x0140-6736$$y2025
000280285 8564_ $$uhttps://pub.dzne.de/record/280285/files/DZNE-2025-00940_Restricted.pdf
000280285 8564_ $$uhttps://pub.dzne.de/record/280285/files/DZNE-2025-00940_Restricted.pdf?subformat=pdfa$$xpdfa
000280285 909CO $$ooai:pub.dzne.de:280285$$pVDB
000280285 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812578$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000280285 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x0
000280285 9141_ $$y2025
000280285 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-16$$wger
000280285 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET : 2022$$d2024-12-16
000280285 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000280285 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000280285 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-16
000280285 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-16
000280285 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000280285 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-16
000280285 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000280285 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-16
000280285 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-16
000280285 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000280285 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000280285 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000280285 915__ $$0StatID:(DE-HGF)9990$$2StatID$$aIF >= 90$$bLANCET : 2022$$d2024-12-16
000280285 9201_ $$0I:(DE-2719)5000071$$kAG Aziz$$lPopulation & Clinical Neuroepidemiology$$x0
000280285 980__ $$ajournal
000280285 980__ $$aVDB
000280285 980__ $$aI:(DE-2719)5000071
000280285 980__ $$aUNRESTRICTED